升降散治疗原发性肝癌栓塞后综合征的临床疗效观察

发布时间：2018-03-12 22:05

本文选题：升降散　切入点：栓塞后综合征　出处：《河南中医药大学》2016年硕士论文　论文类型：学位论文

【摘要】：目的:初步探讨升降散对原发性肝癌栓塞后综合征的临床疗效的影响,为原发性肝癌栓塞后综合征的中医药治疗提供客观的临床依据。方法:选取符合入选标准原发性肝癌患者病例60例,按照随机数字表法进行随机分组。随机等分为治疗组30例,对照组30例。对照组栓塞后给予西医常规治疗,包括静脉补液、抗炎等治疗。治疗组在对照组治疗基础上,于术后第1天至术后第7天服用升降散,连服7天。两组均治疗7天,观察两组患者发热、恶心呕吐、肝区疼痛、便秘症状的发病程度及持续时间。结果:1.对比治疗组与对照组患者发热、恶心呕吐、肝区疼痛、便秘症状栓塞治疗前无显著性差异(P0.05);栓塞治疗后第1天至第7天的对比治疗组与对照组患者,发热、恶心呕吐、肝区疼痛、便秘症状的在术后第3天至术后第6天发生程度差异显著(P0.05);2.栓塞治疗后7天,对比治疗组与对照组患者的发热、恶心呕吐、肝区疼痛、便秘症状的持续时间差异显著(P0.05)。结论:1.升降散能有效减轻原发性肝癌栓塞后综合征的发病程度;2.升降散能有效减少栓塞后综合征的持续时间。
[Abstract]:Objective: to explore the effect of Shengsheng Powder on the clinical effect of primary liver cancer after embolization syndrome. Methods: 60 patients with primary hepatocellular carcinoma (PHC) were selected and randomly divided into treatment group (n = 30) according to random digital table method. The control group (30 cases) was treated with routine western medicine after embolization, including intravenous fluid resuscitation, anti-inflammatory therapy and so on. The treatment group was treated on the basis of the control group from the first day after operation to the seventh day after operation. For 7 days, both groups were treated for 7 days. The incidence and duration of fever, nausea and vomiting, liver pain, constipation symptoms and constipation symptoms in the two groups were observed. Results: 1.Fever, nausea, vomiting and pain in liver region were compared between the treatment group and the control group. There was no significant difference in constipation symptoms before and after embolization (P 0.05). The patients in the control group and the control group had fever, nausea and vomiting, and pain in the liver area from day 1 to day 7 after embolization. The degree of constipation symptoms was significantly different from the 3rd day to the 6th day after operation (P 0.05). 7 days after embolization, fever, nausea and vomiting, pain in the liver area were compared between the treatment group and the control group. The duration of constipation symptoms was significantly different from that of P0.050.Conclusion: 1. Shengghangsan can effectively reduce the severity of post-embolism syndrome of primary hepatocellular carcinoma (PHC). It can effectively reduce the duration of post-embolism syndrome.
【学位授予单位】：河南中医药大学
【学位级别】：硕士
【学位授予年份】：2016
【分类号】：R273

【相似文献】